News express

Drugs targeting the Aβ pathway for AD treatment

The formation of amyloid plaques by Aβ deposition is one of the main pathological features of AD. Therapies that can selectively bind, neutralize and eliminate soluble and toxic Aβ amyloid aggregates are believed to help delay the neurodegenerative process of AD. Including lecanemab that has been marketed, there are currently 5 antibody drugs targeting Aβ pathway for the treatment of AD. 



Advances in drugs targeting Aβ pathway for AD treatment

Although all of them bind to Aβ, they target different aggregation forms of Aβ. Lecanemab targets soluble aggregates of Aβ, including oligomers and protofibril, it has been shown to bind soluble protofibril 10-15 times more than aducanumab and gantenerumab, which also target Aβ. Compared with insoluble aggregates, these soluble fibril and plaques have higher neurotoxicity, which may be the main reason for lecanemab’s better clinical results in phase III.

5 Antibody drugs target different Aβ aggregation forms

Aneuro's new product: Aβ42

Aneuro recently launched recombinant Aβ42 protein（Cat. No. APP-H51H6）, which has been showed to bind specifically to aducanumab with high biological activity. Compared with synthetic peptides, our Aβ42 protein has natural conformation to facilitate the diagnosis and treatment research of AD.

Verification data